Fmr LLC Boosts Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Fmr LLC increased its position in shares of BioNTech SE (NASDAQ:BNTX) by 22.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,701,476 shares of the company’s stock after buying an additional 1,401,547 shares during the period. Fmr LLC owned 3.21% of BioNTech worth $877,583,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BNTX. SG Americas Securities LLC grew its holdings in BioNTech by 412.3% in the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after purchasing an additional 33,375 shares during the period. Mirabaud & Cie SA acquired a new stake in BioNTech in the 4th quarter valued at $684,000. Bank of New York Mellon Corp increased its holdings in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock worth $419,000 after acquiring an additional 150 shares in the last quarter. Vestcor Inc acquired a new position in BioNTech during the third quarter worth $784,000. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in BioNTech during the fourth quarter valued at $1,118,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BNTX. Wells Fargo & Company started coverage on BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target on the stock. Citigroup started coverage on shares of BioNTech in a report on Thursday, March 13th. They set a “buy” rating and a $145.00 target price for the company. BMO Capital Markets increased their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Canaccord Genuity Group restated a “buy” rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Truist Financial assumed coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average price target of $143.44.

BioNTech Stock Performance

BioNTech stock opened at $86.82 on Tuesday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average of $108.15 and a 200-day moving average of $112.59. The stock has a market cap of $20.83 billion, a P/E ratio of -41.34 and a beta of 1.07. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. BioNTech’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, analysts expect that BioNTech SE will post -3.88 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.